A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 3, 2011, Pages 337-345

  Sniderman, Allan D ^a   Williams, Ken ^b   Contois, John H ^c   Monroe, Howard M ^d   McQueen, Matthew J ^e   De Graaf, Jacqueline ^f   Furberg, Curt D ^g  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Maine Standards Company   (United States)

^d OUR LADY OF THE LAKE UNIVERSITY   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoproteins B; Ccardiovascular diseases; Cholesterol HDL; Cholesterol LDL; Meta analysis; Risk

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC TEST; EPIDEMIOLOGICAL DATA; FEMALE; HAZARD RATIO; HEART INFARCTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RISK FACTOR; UNITED STATES;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 79959694696     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.959247     Document Type: Article

References (40)

1. Sniderman AD, Hogue JC, Bergeron J, Gagné C, Couture P Non-HDL cholesterol and apoB in dyslipidaemia Clin Sci (Lond) 2008;114: 149-155.
2. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, deGraaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 2006;259: 247-258.
3. Jeyarajah EJ, Cromwell WC, Otvos JD Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 2006;26: 847-870. (Pubitemid 44716510)
4. Sniderman AD, McQueen MJ, Contois JH, Williams K, Couture P, Furberg CDWhy is non-HDL-cholesterol a better marker of cardiovascular risk than LDL-cholesterol? J Clin Lipidol 2010;4:152-155.
5. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D'Agostino RBLDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management J Clin Lipidol 2007;1:583-592. (Pubitemid 350215511)
6. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J; Emerging Risk Factors CollaborationMajor lipids, apolipoproteins, and risk of vascular disease JAMA 2009;302:1993-2000.
7. Thompson A, Danesh J Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies J Intern Med 2006;259:481-492.
8. Sniderman AD, de Graaf J, Couture P ApoB and the atherogenic apoB dyslipoproteinemias In: Kwiterovich PO JredThe Johns Hopkins Textbook of Dyslipidemia Philadelphia, PA: Lippincott Williams & Wilkins; 2009:196-210.
9. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR Apolipoprotein B and cardiovascular disease risk: position statement from AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 2009;55:407-419.
10. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RSClinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 2007;298:776-785. (Pubitemid 47263160)
11. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines Circulation 2004;110: 2824-2830. (Pubitemid 39473604)
12. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 2009;119:931-939.
13. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-HansenImproving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study Arterioscler Thromb Vasc Biol 2007;27:661-670.
14. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen ANonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 2007;298:299-308. (Pubitemid 47080484)
15. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 2005;294:326-333. (Pubitemid 41043776)
16. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes Diabetes Care 2004; 27:1991-1997. (Pubitemid 38989244)
17. Meisinger C, Loewel H, Mraz W, Koenig W Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study Eur Heart J 2005;26:271-278. (Pubitemid 40222365)
18. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 2005;112: 3375-3783.
19. Bruno G, Merletti F, Biggeri A, Bargero G, Prina-Cerai SPagano G, Cavallo-Perin PEffect of age on the association of non-high-densitylipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study Diabetalogia 2006;49:937-944.
20. Chien KL, Hsu HC, Su TC, Chen MF, Lee TY, Hu FB Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese J Lipid Res 2007;48:2499-2505. (Pubitemid 350058761)
21. Holme E, Aastveit AH, Jungner I, Walldius GRelationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtalityRISk study (AMORIS) J Intern Med 2008;264:30-38. (Pubitemid 351813479)
22. McQueen M, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S; INTERHEART Study InvestigatorsLipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 2008;372:224-233. (Pubitemid 351978112)
23. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S, Youngman L, Sleight P, Collins R; International Studies of Infarct Survival CollaboratorsThe joint effects of apolipoprotein B, apolipoprotein A1, LDL-cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls Eur Heart J 2009;30:2137-2146.
24. NHANES InvestigatorsNational Health and Nutrition Examination Survey.http://www.cdc.gov/nchs/data/nhanes/nhanes-05-06/nhanes-2005-2006- codebook-description.pdf Accessed February 16, 2009.
25. Borenstein M, Hedges LV, Higgins JPT, Rothstein HRIntroduction to Meta-Analysis Chichester, UK; 2009.
26. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 2007;115:450-458. (Pubitemid 46184196)
27. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J; Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors CollaborationTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies Lancet 2010;375:1634-1639.
28. Sniderman AD, Williams K, McQueen MJ, Furberg CD When is equal not equal? J Clin Lipidol 2010;4:83-88.
29. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study Lancet 2004;364:937-952. (Pubitemid 39208455)
30. El Harchaoui K, Arsenault BJ, Franssen R, Després JP, Hovingh GK, Stroes ES, Otvos JD, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SMHigh-density lipoprotein particle size and concentration and coronary risk Ann Intern Med 2009;150:84-93.
31. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone N JImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004;110:227-239. (Pubitemid 38924592)
32. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB Prediction of coronary heart disease using risk factor categories Circulation 1998;97:1837-1847. (Pubitemid 28213628)
33. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SCPrimary and subsequent coronary risk appraisal: new results from the Framingham study Am Heart J 2000;139:272-281. (Pubitemid 30090804)
34. Genest J Jr, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJFamilial hypoalphalipoproteinemia in premature coronary artery disease Arterioscler Thromb 1993;13:1728-1737.
35. Sniderman AD, Dagenais GR, Cantin B, Després JP, Lamarche B High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol Am J Cardiol 2001;87: 792-793. (Pubitemid 32209103)
36. St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men Am J Cardiol 2006;97:997-1001.
37. Sniderman A, Couture P, de Graaf J Diagnosis and treatment of apolipoprotein B dyslipoproteinemias Nat Rev Endocrinol 2010;6:335-346.
38. Sniderman ATargets for LDL-lowering therapy Curr Opin Lipidol 2009;20:282-287.
39. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations Can J Cardiol 2009;25:567-579.
40. Sniderman AD, Scantlebury T, Cianflone K Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus Ann Internal Med 2001;135:447-459. (Pubitemid 32845869)